Stockscreener 앱 받기
13.82
1.58%
0.215
시장 영업 전:
13.60
-0.22
-1.59%
전일 마감가:
$13.61
열려 있는:
$13.98
하루 거래량:
5.88M
Relative Volume:
1.24
시가총액:
$1.60B
수익:
$52.86M
순이익/손실:
$-480.19M
주가수익비율:
-2.9468
EPS:
-4.6899
순현금흐름:
$-421.82M
1주 성능:
+2.98%
1개월 성능:
+11.81%
6개월 성능:
+18.93%
1년 성능:
+51.95%
1일 변동 폭
$13.41
$14.12
1주일 범위
$12.70
$15.51
52주 변동 폭
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
13.82 | 1.58B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-10-28 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain? - simplywall.st
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance
Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial - BioPharma Dive
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading - MarketBeat
This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
NTLA Stock Upgrade: Jones Trading Raises Intellia Therapeutics t - GuruFocus
HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings - MarketBeat
Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026 - Meyka
Intellia (NTLA) CEO John M. Leonard awarded large option and RSU grants - Stock Titan
Intellia (NTLA) EVP receives stock awards and small tax-driven share sale - Stock Titan
Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing - Stock Titan
Intellia Therapeutics (NTLA) CFO granted stock options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) EVP gets stock awards and sells shares for taxes - Stock Titan
Intellia Therapeutics (NTLA) CAO awarded 17,250 restricted stock units - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group - MarketBeat
FDA’s lifting of clinical holds sends Intellia upwards - The Pharma Letter
Intellia Therapeutics (NTLA) Highlights Promising Findings in He - GuruFocus
NTLA: Leerink Partners Raises Price Target and Maintains Outperf - GuruFocus
Leerink Partners Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
NTLA: RBC Capital Raises Price Target to $15, Maintains Sector P - GuruFocus
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial - Sahm
Royal Bank Of Canada Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
Wells Fargo Raises Price Target for Intellia Therapeutics (NTLA) to $15 | NTLA Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
Intellia Therapeutics (NTLA) Highlights Promising Findings in Hereditary Angioedema Treatment - GuruFocus
Citizens Jmp Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
HC Wainwright Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $30.00 - MarketBeat
Vanguard Group Inc. Acquires 192,651 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Chardan Raises Price Target on Intellia Therapeutics to $27 From $26, Keeps Buy Rating - marketscreener.com
NTLA Sees Price Target Raised by Citizens, Rating Maintained | N - GuruFocus
RBC Raises Price Target on Intellia Therapeutics to $15 From $9, Keeps Sector Perform, Speculative Risk - marketscreener.com
Intellia presents data on experimental gene therapy for hereditary angioedema - Investing.com India
NTLA: HC Wainwright & Co. Raises Price Target to $30.00 | NTLA S - GuruFocus
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 - Stock Titan
Demystifying Intellia Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Intellia Therapeutics, Inc. $NTLA is Contrarius Group Holdings Ltd's 6th Largest Position - MarketBeat
BofA Maintains NTLA Neutral for Intellia Therapeutics on Mar 2, 2026 - Meyka
Chardan Capital Raises Price Target for NTLA, Maintains Buy Rati - GuruFocus
Intellia Therapeutics (NTLA) files ATM to sell up to $400M of stock via Jefferies - Stock Titan
Oppenheimer reiterates Intellia stock rating on clinical hold resolution - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7% on Analyst Upgrade - MarketBeat
Intellia Therapeutics Shares Surge Amid Steller Earnings and Promising CRISPR Advances - StocksToTrade
Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Outperform at William Blair - MarketBeat
William Blair Upgrades Intellia Therapeutics to Outperform From Market Perform - marketscreener.com
US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial - WTVB
Intellia Resumes Key Trial and Expands ATM Program - TipRanks
Intellia Therapeutics Says US FDA Removes Clinical Hold on Magnitude Phase 3 Trial for Nexiguran Ziclumeran - marketscreener.com
Intellia Therapeutics Inc increases at-the-market offering program to $1.04 billionSEC filing - marketscreener.com
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):